Share Prices & Company Research

Market News

02 Oct 2018 | 09:53

Alliance Pharma launches nausea and vomiting treatment in UK

Alliance Pharma, a specialty pharmaceutical company, launched its prescription product for the treatment of nausea and vomiting of pregnancy in the UK on Tuesday.

Xonvea, the treatment of nausea and vomiting of pregnancy, was a new licensed medicine available in the UK for women with NVP where conservative management had failed, the company said.

Nausea and vomiting was the most common medical condition in pregnancy affecting approximately 751,923 women in the UK each year, according to the Office of National Statistics and the Royal College of Obstetricians and Gynaecologists.

'The launch of Xonvea is a significant milestone for Alliance and I'm delighted that we have today made the product available in the UK. There is no other licensed treatment for nausea and vomiting of pregnancy in the UK so this is excellent news for patients and clinicians as it fulfils a significant unmet medical need, ' said Peter Butterfield, Alliance Pharma's Chief Executive Officer. At 9:53am: (LON:APH) Alliance Pharma PLC share price was +4.8p at 72.4p

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.